Usmani, Omar
Li, Grace
De Backer, Jan
Sadafi, Hosein
Wu, Libo
Marshall, Jonathan
Funding for this research was provided by:
AstraZeneca (N/A)
Article History
Received: 15 June 2023
Accepted: 8 September 2023
First Online: 23 September 2023
Declarations
:
: All patients gave written informed consent for their HRCT scans to be included in the FLUIDDA database, and ethics approval was granted by the Institutional Review Board (2015-001743-36) of the University Hospital in Antwerp, Belgium. Lung segmentation data obtained from HRCT scans of patients in the FLUIDDA database are the exclusive property of FLUIDDA and did not require additional patient consent for use in this study.
: Not applicable.
: Omar Usmani has received personal fees from Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Mundipharma, NAPP, Prosonix Ltd, Sandoz, Takeda, and Zentiva; and has received research grants from AstraZeneca, Boehringer Ingelheim, Chiesi, and GlaxoSmithKline. Grace Li, Libo Wu, and Jonathan Marshall are employees of AstraZeneca and hold stock and/or stock options in the company. Jan De Backer and Hosein Sadafi are employees of FLUIDDA, who received funding from AstraZeneca for this study.